Superworth

Eli Lilly and price to free cash flow LLY

Market value divided by free cash flow over the last twelve months, since 2009.

Today, Oct 23, 2026
65.9×
10-year median
39.6×
Against its 10-year history
74th
percentile: 0 is its lowest day, 100 its highest
10-year range
17.0× to 492×
Peer median
18.9×

Eli Lilly and's price to free cash flow is 65.9× as of Oct 23, 2026.

That is above its ten-year median of 39.6×, higher than on 74% of days in the last ten years.

Over that time it ranged from 17.0× in Feb 2018 to 492× in Jan 2025.

The median for 7 large drugmakers of a similar size is 18.9×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far65.9×57.7×111×
2025110×88.0×492×
2024228×180×228×
2023170×51.9×175×
202257.8×40.1×59.5×
202148.5×27.5×48.5×
202030.0×23.2×43.7×
201939.2×24.6×39.5×
201826.5×17.0×28.4×
201718.8×17.9×35.1×
201632.1×29.5×60.1×
201542.0×22.1×43.2×
201422.2×12.4×22.9×
201312.4×12.0×16.3×
201211.5×6.6×11.9×
20117.0×6.0×8.3×
20108.2×7.9×11.9×
20098.3×7.0×8.7×

Against its peers

Companies in Drug Manufacturers - General nearest Eli Lilly and's size, closest first, today.

CompanyPrice to free cash flow
LLYEli Lilly and65.9×
JNJJohnson & Johnsonn/m
ABBVAbbVie27.7×
MRKMerck22.3×
AMGNAmgen23.3×
GILDGilead Sciences14.9×
PFEPfizer15.6×
BMYBristol-Myers Squibb11.0×
Peer median18.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Eli Lilly and

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.